Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing

Chuikyo Drug Pricing Subcommittee Meeting on Nov. 5 Both payer and healthcare provider members of Japan’s key drug pricing panel on November 5 called for controlling spending of potentially super-big-seller medicines that might rake in annual revenue of hundreds of...read more